Detalles de la búsqueda
1.
Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.
Diabetes Obes Metab
; 2024 May 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38764356
2.
Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study.
Front Pharmacol
; 15: 1358573, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38601470
3.
Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication.
Diab Vasc Dis Res
; 20(6): 14791641231222837, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38096503
4.
The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists.
Cardiovasc Endocrinol Metab
; 12(4): e0292, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37779602
5.
Nivolumab-induced fulminant type 1 diabetes with precipitous fall in C-peptide level.
J Diabetes Investig
; 11(3): 748-749, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-31587459
6.
Detection of Autonomic Nervous System Abnormalities in Diabetic Patients by 24-hour Ambulatory Blood Pressure Monitoring.
Tokai J Exp Clin Med
; 43(3): 97-102, 2018 Sep 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-30191543
7.
Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor.
Intern Med
; 56(13): 1673-1678, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28674356
8.
Glomerular expression of CTGF, TGF-beta 1 and type IV collagen in diabetic nephropathy.
J Nephrol
; 19(6): 751-7, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-17173248
9.
[Case of rheumatoid arthritis with various histological lesions of the kidney].
Nihon Jinzo Gakkai Shi
; 48(2): 67-73, 2006.
Artículo
en Japonés
| MEDLINE | ID: mdl-16541759
10.
[Clinical significance of IgM deposition in the mesangium and mesangial hypercellularity in adult minimal change nephrotic syndrome].
Nihon Jinzo Gakkai Shi
; 48(1): 14-21, 2006.
Artículo
en Japonés
| MEDLINE | ID: mdl-16480062
11.
Exercise Therapy for Management of Type 2 Diabetes Mellitus: Superior Efficacy of Activity Monitors over Pedometers.
J Diabetes Res
; 2016: 5043964, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27761471
12.
Upregulation of α3ß1-Integrin in Podocytes in Early-Stage Diabetic Nephropathy.
J Diabetes Res
; 2016: 9265074, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27340677
13.
Long-term glycemic control in Japanese type 2 diabetes patients after switching treatment from twice-daily premixed insulin to once daily insulin glargine.
Tokai J Exp Clin Med
; 38(1): 28-32, 2013 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-23564573
14.
Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.
Intern Med
; 52(10): 1029-34, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23676586
15.
Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis.
J Nephrol
; 25(6): 989-95, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22307438
16.
Expression of transcription factor Snai1 and tubulointerstitial fibrosis in progressive nephropathy.
J Nephrol
; 25(2): 233-9, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-21725924
17.
Efficacy of long-acting insulin analog insulin glargine at high dosage for basal-bolus insulin therapy in patients with type 2 diabetes.
Tokai J Exp Clin Med
; 37(2): 35-40, 2012 Jul 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-22763825
18.
Effectiveness of basal-supported oral therapy (BOT) using insulin glargine in patients with poorly controlled type 2 diabetes.
Tokai J Exp Clin Med
; 37(2): 41-6, 2012 Jul 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-22763826
19.
Lectin-like oxidized LDL receptor-1 (LOX-1) expression in the tubulointerstitial area likely plays an important role in human diabetic nephropathy.
Intern Med
; 48(4): 189-94, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19218767
20.
Hypertrophy and loss of podocytes in diabetic nephropathy.
Intern Med
; 48(18): 1615-20, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19755763